ES2591028T3 - Composiciones de inhibidores de quinasa y su uso para el tratamiento del cáncer y otras enfermedades relacionadas con quinasas - Google Patents

Composiciones de inhibidores de quinasa y su uso para el tratamiento del cáncer y otras enfermedades relacionadas con quinasas Download PDF

Info

Publication number
ES2591028T3
ES2591028T3 ES08829600.9T ES08829600T ES2591028T3 ES 2591028 T3 ES2591028 T3 ES 2591028T3 ES 08829600 T ES08829600 T ES 08829600T ES 2591028 T3 ES2591028 T3 ES 2591028T3
Authority
ES
Spain
Prior art keywords
substituted
heterocycle
alkyl
aryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08829600.9T
Other languages
English (en)
Spanish (es)
Inventor
Chiang Jia Li
Ji-Feng Liu
Youzhi Li
Wei Li
Harry Rogoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Oncology Inc
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Application granted granted Critical
Publication of ES2591028T3 publication Critical patent/ES2591028T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
ES08829600.9T 2007-09-06 2008-09-05 Composiciones de inhibidores de quinasa y su uso para el tratamiento del cáncer y otras enfermedades relacionadas con quinasas Active ES2591028T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US97041007P 2007-09-06 2007-09-06
US970410P 2007-09-06
US1338907P 2007-12-13 2007-12-13
US13389P 2007-12-13
US7429508P 2008-06-20 2008-06-20
US74295P 2008-06-20
PCT/US2008/075418 WO2009033033A2 (en) 2007-09-06 2008-09-05 Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases

Publications (1)

Publication Number Publication Date
ES2591028T3 true ES2591028T3 (es) 2016-11-24

Family

ID=40429714

Family Applications (2)

Application Number Title Priority Date Filing Date
ES08829600.9T Active ES2591028T3 (es) 2007-09-06 2008-09-05 Composiciones de inhibidores de quinasa y su uso para el tratamiento del cáncer y otras enfermedades relacionadas con quinasas
ES16156340T Active ES2759347T3 (es) 2007-09-06 2008-09-05 Composiciones de inhibidores de quinasas y su uso para el tratamiento del cáncer y otras enfermedades relacionadas con las quinasas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16156340T Active ES2759347T3 (es) 2007-09-06 2008-09-05 Composiciones de inhibidores de quinasas y su uso para el tratamiento del cáncer y otras enfermedades relacionadas con las quinasas

Country Status (15)

Country Link
US (5) US8299106B2 (enExample)
EP (2) EP3037419B1 (enExample)
JP (5) JP5452490B2 (enExample)
CN (1) CN101848908B (enExample)
CA (1) CA2736177A1 (enExample)
CY (1) CY1118012T1 (enExample)
DK (1) DK2197878T3 (enExample)
ES (2) ES2591028T3 (enExample)
HR (1) HRP20161114T1 (enExample)
HU (1) HUE030774T2 (enExample)
LT (1) LT2197878T (enExample)
PL (1) PL2197878T3 (enExample)
PT (1) PT2197878T (enExample)
SI (1) SI2197878T1 (enExample)
WO (1) WO2009033033A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5452490B2 (ja) * 2007-09-06 2014-03-26 ボストン バイオメディカル， インコーポレイテッド キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
TW201511499A (zh) * 2007-12-10 2015-03-16 Interdigital Patent Holdings 無縣電鏈路控制封包丟棄及無線電鏈路控制重建觸發方法及裝置
JP2014509323A (ja) 2011-02-28 2014-04-17 マックマスター ユニヴァーシティ ドーパミン受容体遮断薬による癌の処置
EP2888254B1 (en) 2012-08-23 2016-10-05 The Institute of Cancer Research: Royal Cancer Hospital Fused heterocyclic compounds and their use
US9187454B2 (en) 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
HK1220184A1 (zh) 2013-03-13 2017-04-28 Boston Biomedical, Inc. 用於治疗癌症的作为癌症干细胞途径激酶抑制剂的3-(芳基或杂芳基)甲基吲哚-2-酮衍生物
US9227962B2 (en) 2013-03-13 2016-01-05 Boston Biomedical, Inc. Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative
US20160368870A1 (en) * 2013-06-20 2016-12-22 Boehringer Ingelheim International Gmbh Olefin substituted oxindoles having ampk activity
EP3099297A4 (en) * 2014-01-27 2017-06-07 Boston Biomedical, Inc. Novel methods for treating cancer
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
EP3288552A1 (en) * 2015-04-27 2018-03-07 Boston Biomedical, Inc. Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
US10377749B2 (en) 2015-08-10 2019-08-13 Sumitomo Dainippon Pharma Co., Ltd. Purification method for 5-(thiazol-4-yl)indolin-2-one derivative
WO2017160978A1 (en) 2016-03-15 2017-09-21 Boston Biomedical, Inc. Cell cultures and use thereof
CA3029596A1 (en) 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
US12390460B2 (en) 2018-09-18 2025-08-19 1Globe Biomedical Co., Ltd. Treatment for obesity
EP3852753A4 (en) * 2018-09-18 2022-06-08 1Globe Biomedical Co., Ltd. TREATMENT OF NONALCOHOLIC FAT LIVER DISEASE
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2074933C (en) * 1990-11-30 2002-12-03 Masatoshi Chihiro Thiazole derivatives as active superoxide radical inhibitors
AU4155697A (en) * 1996-08-23 1998-03-06 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
JP2001517666A (ja) * 1997-09-23 2001-10-09 藤沢薬品工業株式会社 チアゾール誘導体
AR034118A1 (es) * 2000-02-15 2004-02-04 Sugen Inc Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis
AU2001241798A1 (en) 2000-02-28 2001-09-12 Sugen, Inc. 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
AU2001268154A1 (en) * 2000-06-02 2001-12-17 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US20030165873A1 (en) * 2001-03-02 2003-09-04 Come Jon H. Three hybrid assay system
WO2002081466A1 (en) * 2001-04-09 2002-10-17 Sugen, Inc. Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US20030119839A1 (en) * 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
US20050032871A1 (en) * 2002-09-03 2005-02-10 Sugen, Inc. Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
US7105563B2 (en) * 2003-10-24 2006-09-12 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
PL1973910T3 (pl) * 2006-01-27 2013-11-29 Shanghai hengrui pharmaceutical co ltd Pirolo[3,2-c]pirydyn-4-onowo-2-indolinonowe inhibitory kinazy białkowej
ATE518857T1 (de) * 2007-06-01 2011-08-15 Hoffmann La Roche Piperidin-amidderivate
JP5452490B2 (ja) * 2007-09-06 2014-03-26 ボストン バイオメディカル， インコーポレイテッド キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof

Also Published As

Publication number Publication date
US20100285006A1 (en) 2010-11-11
PT2197878T (pt) 2016-11-04
PL2197878T3 (pl) 2017-01-31
JP5701372B2 (ja) 2015-04-15
CN101848908A (zh) 2010-09-29
US20190248781A1 (en) 2019-08-15
US8299106B2 (en) 2012-10-30
JP2015129152A (ja) 2015-07-16
HRP20161114T1 (hr) 2016-11-04
JP2014058573A (ja) 2014-04-03
EP3037419B1 (en) 2019-09-04
HUE030774T2 (hu) 2017-05-29
JP5452490B2 (ja) 2014-03-26
EP2197878A2 (en) 2010-06-23
WO2009033033A2 (en) 2009-03-12
CA2736177A1 (en) 2009-03-12
WO2009033033A3 (en) 2009-04-30
LT2197878T (lt) 2016-09-26
CN101848908B (zh) 2014-07-02
HK1226071A1 (en) 2017-09-22
US20180022743A1 (en) 2018-01-25
US20120321622A1 (en) 2012-12-20
JP5974124B2 (ja) 2016-08-23
HK1148529A1 (en) 2011-09-09
ES2759347T3 (es) 2020-05-08
CY1118012T1 (el) 2017-05-17
EP3037419A1 (en) 2016-06-29
EP2197878B1 (en) 2016-08-17
EP2197878A4 (en) 2012-02-08
JP2016180013A (ja) 2016-10-13
JP2010538091A (ja) 2010-12-09
JP6495868B2 (ja) 2019-04-03
JP2019070051A (ja) 2019-05-09
US9725444B2 (en) 2017-08-08
US20150197517A1 (en) 2015-07-16
DK2197878T3 (en) 2016-11-14
SI2197878T1 (sl) 2016-10-28

Similar Documents

Publication Publication Date Title
ES2759347T3 (es) Composiciones de inhibidores de quinasas y su uso para el tratamiento del cáncer y otras enfermedades relacionadas con las quinasas
ES2933601T3 (es) Compuestos útiles como inmunomoduladores
ES2998139T3 (en) 2,8-diacyl-2,8-diazaspiro[5.5]undecane compounds useful as immunomodulators
ES2384123T3 (es) Compuestos para inhibir la progresión mitótica
ES2702707T3 (es) Inhibidores de DNA-PK
KR20240089594A (ko) 질소 함유 테트라시클릭 화합물, 이의 제조 방법 및 이의 의학적 응용
CN112867721A (zh) Sting激动性化合物
ES2609296T3 (es) Análogos de triazina y su uso como agentes terapéuticos y sondas de diagnóstico
WO2021249563A1 (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
AU2013227024A1 (en) Novel piperidine compound or salt thereof
ES2338060T3 (es) Componentes de tipo ariloxi y ariltoxia-cetofenona para el tratamiento del cancer.
ES2782113T3 (es) Compuestos de quinolina fusionados como inhibidores de PI3K/mTor
CN103509030A (zh) 喜树碱类化合物及其制备和用途
ES2352748T3 (es) Fenilaminopiridinas y fenilaminopiracinas.
CN109988151A (zh) 一种炔类化合物、制备方法及其应用
WO2021206158A1 (ja) がん治療方法
ES2956866T3 (es) Inmunomoduladores heterocíclicos como inhibidor del punto de control del pdl1
HK1226071B (en) Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
HK40053745A (en) Sting-agonist compound
HK1148529B (en) Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
HK40053745B (zh) Sting激动性化合物